VSIR and neoplasm: VISTA has been identified as a critical mediator of cancer immune tolerance through its mechanisms of inhibiting the activation of tumor-responsive T cells and myeloid cells in addition to enhancing the presence and function of tolerogenic immune populations in the TME (Fig. 1).